IN8BIO, Inc.
NASDAQ:INAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
IN8BIO, Inc.
Pre-Tax Income
IN8BIO, Inc.
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
IN8BIO, Inc.
NASDAQ:INAB
|
Pre-Tax Income
-$19.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$6.6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
14%
|
CAGR 10-Years
0%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$9.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
42%
|
CAGR 10-Years
-8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$5.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
16%
|
|
IN8BIO, Inc.
Glance View
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 19 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. The firm develops ex vivo-expanded and activated gamma-delta T cell candidates based upon its capabilities in gamma-delta T cell biology, genetic engineering and cell-type-specific manufacturing capabilities, DeltEx platform. Its lead product candidate, INB-200, is a genetically modified autologous gamma-delta T cell in Phase I clinical trial. Its INB-100, its off-the-shelf allogeneic DeltEx product candidate, was developed to demonstrate the safety of donor-derived expanded and activated gamma-delta T cells that do not undergo additional genetic modification. Its INB-400 is its allogeneic DeltEx DRI product candidate to treat solid tumor cancers, including newly diagnosed glioblastoma (GBM). Its INB-300 is a preclinical program focused on developing CAR-T-enabled DeltEx DRI product candidates.
See Also
What is IN8BIO, Inc.'s Pre-Tax Income?
Pre-Tax Income
-19.4m
USD
Based on the financial report for Dec 31, 2025, IN8BIO, Inc.'s Pre-Tax Income amounts to -19.4m USD.
What is IN8BIO, Inc.'s Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-18%
Over the last year, the Pre-Tax Income growth was 36%. The average annual Pre-Tax Income growth rates for IN8BIO, Inc. have been 12% over the past three years , -18% over the past five years .
